Nama's AI scorecard currently rates Arcus Biosciences Sell (2.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does RCUS report earnings?

Arcus Biosciences's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.84.

What is the RCUS price target?

The median analyst price target from 12 analysts is $43.50, with a range of $23.00 – $50.00.

Is RCUS Shariah compliant?

Nama's AAOIFI-style screen reads Arcus Biosciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Arcus Biosciences (RCUS)

Healthcare · Biotechnology · NYSE

Arcus Biosciences (RCUS) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.63B and a free-cash-flow yield of -24.7%. Over the most recent reported fiscal year, revenue declined 4.3%. Nama's AI scorecard rates it Sell, 2.0 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 2.0/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Middle · +25.4% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-62.8%

How far the last close sits under the highest price of the past five years.

Market cap	$2.63B
Trailing P/E	—
Price / book	5.0
Price / sales	19.7
FCF yield	-24.7%
Dividend yield	—
Gross margin	0.0%
Operating margin	-234.2%
Net margin	0.0%
Revenue growth (YoY)	-4.3%
Revenue growth (3-yr annual)	+30.2%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.9
Exchange	NYSE
Sector	Healthcare
Industry	Biotechnology

RCUS earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate -$0.84). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$1.00	-$0.89	-12.4%	$9.00M
Q2 2026	Aug 5, 2026	-$0.72	-$0.81	+11.1%	$41.00M
Q1 2026	May 5, 2026	-$1.02	-$0.83	-22.9%	$17.00M
Q4 2025	Feb 25, 2026	-$0.89	-$1.07	+16.8%	$33.00M

RCUS analyst price target

Median target $43.50 from 12 analysts, ranging $23.00 – $50.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live RCUS data on Nama Insights →

RCUS FAQ

Is RCUS a buy?: Nama's AI scorecard currently rates Arcus Biosciences Sell (2.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does RCUS report earnings?: Arcus Biosciences's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.84.
What is the RCUS price target?: The median analyst price target from 12 analysts is $43.50, with a range of $23.00 – $50.00.
Is RCUS Shariah compliant?: Nama's AAOIFI-style screen reads Arcus Biosciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.